KR20190084056A - 인간 지방간염(nafld/nash)의 치료 및 역행을 위한 서방성 피르페니돈 함유 조성물의 약학적 용도 - Google Patents

인간 지방간염(nafld/nash)의 치료 및 역행을 위한 서방성 피르페니돈 함유 조성물의 약학적 용도 Download PDF

Info

Publication number
KR20190084056A
KR20190084056A KR1020197014274A KR20197014274A KR20190084056A KR 20190084056 A KR20190084056 A KR 20190084056A KR 1020197014274 A KR1020197014274 A KR 1020197014274A KR 20197014274 A KR20197014274 A KR 20197014274A KR 20190084056 A KR20190084056 A KR 20190084056A
Authority
KR
South Korea
Prior art keywords
liver
nash
nafld
treatment
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197014274A
Other languages
English (en)
Korean (ko)
Inventor
후안 소코로 아르멘다리즈 보룬다
호세 아구스틴 로헬리오 마가나 캐스트로
나디엘 헤르난데즈 알다나
Original Assignee
셀 테라피 앤드 테크놀로지, 에스.에이. 디이 씨.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 셀 테라피 앤드 테크놀로지, 에스.에이. 디이 씨.브이. filed Critical 셀 테라피 앤드 테크놀로지, 에스.에이. 디이 씨.브이.
Priority to KR1020247015017A priority Critical patent/KR20240065330A/ko
Publication of KR20190084056A publication Critical patent/KR20190084056A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020197014274A 2016-11-11 2017-11-09 인간 지방간염(nafld/nash)의 치료 및 역행을 위한 서방성 피르페니돈 함유 조성물의 약학적 용도 Ceased KR20190084056A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247015017A KR20240065330A (ko) 2016-11-11 2017-11-09 인간 지방간염(nafld/nash)의 치료 및 역행을 위한 서방성 피르페니돈 함유 조성물의 약학적 용도

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
MXMX/A/2016/014775 2016-11-11
MX2016014775A MX364040B (es) 2016-11-11 2016-11-11 Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash).
PCT/MX2017/000129 WO2018088886A1 (es) 2016-11-11 2017-11-09 Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247015017A Division KR20240065330A (ko) 2016-11-11 2017-11-09 인간 지방간염(nafld/nash)의 치료 및 역행을 위한 서방성 피르페니돈 함유 조성물의 약학적 용도

Publications (1)

Publication Number Publication Date
KR20190084056A true KR20190084056A (ko) 2019-07-15

Family

ID=61193005

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197014274A Ceased KR20190084056A (ko) 2016-11-11 2017-11-09 인간 지방간염(nafld/nash)의 치료 및 역행을 위한 서방성 피르페니돈 함유 조성물의 약학적 용도
KR1020247015017A Ceased KR20240065330A (ko) 2016-11-11 2017-11-09 인간 지방간염(nafld/nash)의 치료 및 역행을 위한 서방성 피르페니돈 함유 조성물의 약학적 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020247015017A Ceased KR20240065330A (ko) 2016-11-11 2017-11-09 인간 지방간염(nafld/nash)의 치료 및 역행을 위한 서방성 피르페니돈 함유 조성물의 약학적 용도

Country Status (21)

Country Link
US (3) US20190262325A1 (enExample)
EP (1) EP3539537A1 (enExample)
JP (2) JP2019535822A (enExample)
KR (2) KR20190084056A (enExample)
CN (2) CN110248646A (enExample)
AR (1) AR110057A1 (enExample)
AU (2) AU2017358367B2 (enExample)
CA (1) CA3043300A1 (enExample)
CL (1) CL2019001280A1 (enExample)
CO (1) CO2019004799A2 (enExample)
EC (1) ECSP19031851A (enExample)
IL (1) IL266519A (enExample)
JO (1) JOP20190102A1 (enExample)
MA (1) MA45754A1 (enExample)
MX (1) MX364040B (enExample)
PE (1) PE20191149A1 (enExample)
PH (1) PH12019501047A1 (enExample)
RU (1) RU2019116422A (enExample)
UY (1) UY37478A (enExample)
WO (1) WO2018088886A1 (enExample)
ZA (1) ZA201903012B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
MX366086B (es) 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.
EP3716975A4 (en) * 2017-11-28 2022-01-12 Eiger Biopharmaceuticals, Inc. METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS
WO2020115774A1 (en) 2018-12-06 2020-06-11 Cipla Limited High drug load extended release formulations
EP4232063A4 (en) * 2020-10-23 2025-01-01 HAN, Hq BIFUNCTIONAL ANTAGONISTS OF TUMOR NECROSIS FACTOR-ALPHA AND TRANSFORMING GROWTH FACTOR-BETA AND THEIR USES
CN117007806A (zh) * 2023-09-21 2023-11-07 中国人民解放军军事科学院军事医学研究院 靶向肝巨噬细胞内lxr用于控制慢乙肝进展

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60234812D1 (de) * 2001-01-29 2010-02-04 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält
US20080025986A1 (en) * 2003-06-06 2008-01-31 Ozes Osman N Methods of Treating Tnf-Mediated Disorders
CN100542532C (zh) * 2004-05-24 2009-09-23 上海睿星基因技术有限公司 吡非尼酮在制备治疗肝损伤坏死和急性肺损伤的药物中的用途
WO2010048716A1 (en) * 2008-10-29 2010-05-06 Pacific Therapeutics Ltd. Composition and method for treating fibrosis
US7635707B1 (en) * 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
CN101972236A (zh) * 2010-10-13 2011-02-16 北京诚创康韵医药科技有限公司 一种含吡非尼酮的缓释制剂
MX2011007675A (es) * 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
CN102488660A (zh) * 2011-12-15 2012-06-13 西安天一秦昆制药有限责任公司 一种含吡非尼酮的缓释微丸
CN103550242B (zh) * 2013-11-22 2015-07-15 四川国康药业有限公司 一种治疗肝纤维化的药物组合物及其制备方法

Also Published As

Publication number Publication date
AR110057A1 (es) 2019-02-20
CL2019001280A1 (es) 2019-07-19
IL266519A (en) 2019-07-31
AU2024200737A1 (en) 2024-02-22
JP2019535822A (ja) 2019-12-12
EP3539537A1 (en) 2019-09-18
AU2017358367A1 (en) 2019-05-30
MX364040B (es) 2019-04-11
PH12019501047A1 (en) 2019-12-11
ZA201903012B (en) 2020-09-30
RU2019116422A (ru) 2020-12-11
AU2017358367B2 (en) 2023-11-09
US20250325530A1 (en) 2025-10-23
JP2022173344A (ja) 2022-11-18
CA3043300A1 (en) 2018-05-17
CN110248646A (zh) 2019-09-17
US20230181550A1 (en) 2023-06-15
ECSP19031851A (es) 2019-06-30
MA45754A1 (fr) 2019-12-31
US20190262325A1 (en) 2019-08-29
PE20191149A1 (es) 2019-09-02
JOP20190102A1 (ar) 2019-05-06
RU2019116422A3 (enExample) 2021-04-09
CN115969802A (zh) 2023-04-18
WO2018088886A1 (es) 2018-05-17
CO2019004799A2 (es) 2019-07-31
KR20240065330A (ko) 2024-05-14
UY37478A (es) 2018-05-31
MX2016014775A (es) 2018-05-10

Similar Documents

Publication Publication Date Title
KR20190084056A (ko) 인간 지방간염(nafld/nash)의 치료 및 역행을 위한 서방성 피르페니돈 함유 조성물의 약학적 용도
CA2949644C (en) Composition for treating or preventing metabolic disease, containing, as active ingredient, extracellular vesicles derived from akkermansia muciniphila bacteria
JP2022095884A (ja) 単離ミトコンドリアを含む関節リウマチの予防または治療のための医薬組成物
Xu et al. Orally administered ginkgolide C attenuates DSS-induced colitis by maintaining gut barrier integrity, inhibiting inflammatory responses, and regulating intestinal flora
JPWO2019156137A1 (ja) 乾癬の治療薬
Metlakunta et al. Kupffer cells facilitate the acute effects of leptin on hepatic lipid metabolism
US20170049773A1 (en) Pharmaceutical composition containing gpr119 ligand as active ingredient for preventing or treating non-alcoholic fatty liver disease
KR20240035920A (ko) 신규한 글루타미닐 고리화효소 억제제 및 다양한 질환의 치료에서의 이의 용도
RU2727142C2 (ru) Бисамидное производное дикарбоновой кислоты в качестве средства, стимулирующего регенерацию тканей и восстановление сниженных функций тканей
JP2021527669A (ja) 線維症の軽減又は治療のための組成物及び方法
Sanhueza‐Olivares et al. Vascular remodelling in a mouse model of heart failure with preserved ejection fraction
KR101706868B1 (ko) 2-아미노-2-노보네인카복실산을 함유하는 지방간염의 예방 또는 치료용 조성물
JP7411875B2 (ja) ベータ－ラパコンを有効成分として含む胆汁うっ滞性肝疾患予防又は治療用薬学組成物
CN114848643B (zh) 异莲心碱在制备预防或治疗结肠炎药物中的应用
RU2807743C1 (ru) Применение 5-пентадецилрезорцинола для повышения доли Akkermansia muciniphila в микробиоме человека
Hamam et al. Effect of pirfenidone on cardiac complications in a model of Kawasaki disease in female Balb/C Mice: Histological and Immunohistochemical study
Askar et al. A Histological Study of The Protective Role of Intermittent Fasting and Probiotics on Indomethacin Induced Colitis in Adult Male Albino Rats.
CN119970730A (zh) 哌啶酸在制备预防和/或治疗非酒精性脂肪性肝炎药物中的应用
CN112972440B (zh) 麝香酮在制备防治抑郁症的药物中的用途
CN119970721A (zh) 吲哚乙酸在制备预防和/或治疗脂肪肝肝纤维化药物中的应用
JP6936496B2 (ja) 移植片対宿主病の治療剤又は予防剤、ファイブロサイト浸潤抑制剤、及び涙液減少と杯細胞の減少の抑制剤
KR100627750B1 (ko) 암톨메틴 구아실의 장내 염증용 소염제 제조를 위한 용도
CN118078849A (zh) 白头翁皂苷b4衍生物a3-9在制备防治炎症性肠病药物中的应用
CN119031908A (zh) 用于治疗炎性肠病的gpr120激动剂
HK40083624A (en) Compositions and methods for treating non-alcoholic steatohepatitis (nash)

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190517

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201106

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230703

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20231204

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230703

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I